Drug Profile
Research programme: angiogenesis/lymphangiogenesis inhibitors - AsclepiX Therapeutics
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator AsclepiX Therapeutics
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Solid-tumours(Adjuvant therapy) in USA
- 28 Aug 2020 No recent reports of development identified for research development in Solid-tumours(Neoadjuvant therapy) in USA